137 related articles for article (PubMed ID: 38385408)
21. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
23. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients.
Akbulut S; Kayaalp C; Yilmaz M; Ince V; Ozgor D; Karabulut K; Eris C; Toprak HI; Aydin C; Yilmaz S
World J Gastroenterol; 2013 Mar; 19(10):1625-31. PubMed ID: 23538988
[TBL] [Abstract][Full Text] [Related]
24. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
25. Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma.
Kim YK; Kim SH; Lee SD; Lee SA; Park SJ
Hepatobiliary Pancreat Dis Int; 2014 Jun; 13(3):250-8. PubMed ID: 24919607
[TBL] [Abstract][Full Text] [Related]
26. Outcome of Living-Donor Liver Transplant for Hepatocellular Carcinoma: 15-Year Single-Center Experience in Egypt.
Kamel R; Hatata Y; Hosny K; Nabil A; El-Deen Abd-Allah A; Mostafa A; Abdel-Aal A; Elganzoury MZ; Elmalt O; Marwan I; Hosny A
Exp Clin Transplant; 2017 Mar; 15(Suppl 2):12-20. PubMed ID: 28301993
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
Llovet JM; Pavel M; Rimola J; Diaz MA; Colmenero J; Saavedra-Perez D; Fondevila C; Ayuso C; Fuster J; Ginès P; Bruix J; Garcia-Valdecasas JC
Liver Transpl; 2018 Mar; 24(3):369-379. PubMed ID: 29140601
[TBL] [Abstract][Full Text] [Related]
28. Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients.
Tsou YF; Lin NC; Hsia CY; Loong CC; Tsai HL; Chen CY; Lei HJ; Chou SC; Chung MH; Kuo FC; Liu CS
J Chin Med Assoc; 2022 Mar; 85(3):317-323. PubMed ID: 34812768
[TBL] [Abstract][Full Text] [Related]
29. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
DiNorcia J; Florman SS; Haydel B; Tabrizian P; Ruiz RM; Klintmalm GB; Senguttuvan S; Lee DD; Taner CB; Verna EC; Halazun KJ; Hoteit M; Levine MH; Chapman WC; Vachharajani N; Aucejo F; Nguyen MH; Melcher ML; Tevar AD; Humar A; Mobley C; Ghobrial M; Nydam TL; Amundsen B; Markmann JF; Berumen J; Hemming AW; Langnas AN; Carney CA; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Ann Surg; 2020 Apr; 271(4):616-624. PubMed ID: 30870180
[TBL] [Abstract][Full Text] [Related]
30. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.
Mahmud N; Shaked A; Olthoff KM; Goldberg DS
Liver Transpl; 2019 Mar; 25(3):388-398. PubMed ID: 30362249
[TBL] [Abstract][Full Text] [Related]
31. Tumor Characteristics and Long-Term Outcome of Incidental Hepatocellular Carcinoma After Orthotopic Liver Transplant.
Mourad MM; Algarni A; Aly MA; Gunson BK; Mergental H; Isaac J; Muiesan P; Mirza D; Perera MT; Bramhall SR
Exp Clin Transplant; 2015 Aug; 13(4):333-8. PubMed ID: 26295183
[TBL] [Abstract][Full Text] [Related]
32. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
[TBL] [Abstract][Full Text] [Related]
33. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
[TBL] [Abstract][Full Text] [Related]
34. Decrease in the Risk of Posttransplant Hepatocellular Carcinoma Recurrence After the Conversion to Prestorage Leukoreduction for Transfused Red Blood Cells.
Kwon JH; Han S; Jang JS; Lee KW; Ahn JH; Kim K; Jeon S; Gwak MS; Ko JS; Kim GS; Joh JW; Cho D
Transplantation; 2021 Mar; 105(3):577-585. PubMed ID: 32265418
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma.
Werner JD; Frangakis C; Ruck JM; Hong K; Philosophe B; Cameron AM; Saberi B; Gurakar A; Georgiades C
Exp Clin Transplant; 2019 Oct; 17(5):638-643. PubMed ID: 30251938
[TBL] [Abstract][Full Text] [Related]
36. More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma.
Hogen R; Lo M; DiNorcia J; Ji L; Genyk Y; Sher L; Dhanireddy K
Transplantation; 2019 Apr; 103(4):747-754. PubMed ID: 29672442
[TBL] [Abstract][Full Text] [Related]
37. Low Utility of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Detecting Hepatocellular Carcinoma in Patients Before Liver Transplantation.
Alotaibi F; Kabbani M; Abaalkhail F; Chorley A; Elbeshbeshy H; Al-Hamoudi W; Alabbad S; Boehnert MU; Alsofayan M; Al-Kattan W; Ahmed B; Broering D; Al Sebayel M; Elsiesy H
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):37-41. PubMed ID: 28260429
[TBL] [Abstract][Full Text] [Related]
38. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
Silverstein J; Roll G; Dodge JL; Grab JD; Yao FY; Mehta N
Liver Transpl; 2020 Sep; 26(9):1100-1111. PubMed ID: 32531867
[TBL] [Abstract][Full Text] [Related]
39. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
40. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
